ASCO 2024: Lung cancer highlights

EHA 2024: Multiple myeloma roundup

Whole body-MRI and fluorine 18 fluorodeoxyglucose PET/CT shows promising diagnostic accuracy in multiple myeloma patients

ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia

More effective treatment options required for patients with MM post lenalidomide exposure

Ibrutinib and venetoclax continue to provide benefits for patients with chronic CLL and SLL

Combination of zanubrutinib and venetoclax shows promise in high-risk TN CLL/SLL with del(17p) and/or TP53 mutation

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM

PD-1–refractory advanced melanoma: how do we get to the finish line?

3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab in resected melanoma

Immunotherapy significantly increases the number of patients free from bowel cancer

Encouraging results using mismatched unrelated donors in stem cell transplantation